We are investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Kadmon Holdings, Inc. (“Kadmon Holdings” or the “Company”) (NASDAQ: KDMN) in connection with the proposed acquisition of the Company by Sanofi (“Sanofi”) (NASDAQ: SNY). Under the terms of the merger agreement, the Company’s shareholders will receive $9.50 per share in cash for each share of Kadmon Holdings common stock that they hold.  The transaction is valued at approximately $1.9 billion.

WeissLaw LLP is investigating whether (i) Kadmon Holdings’ board of directors acted in the best interests of Company shareholders in agreeing to the proposed transaction, (ii) the $9.50 per-share merger consideration adequately compensates Kadmon Holdings’ shareholders, and (iii) all information regarding the sales process and valuation of the transaction will be fully and fairly disclosed.  Notably, the merger consideration is below the $10.75 median of price targets set by analysts following the Company and at least one analyst set a price target for the Company of $20.00 per share, $10.50 above the per-share merger consideration.